Compare NextEra Energy, Inc. (NEE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Sanofi SA — how do they compare? NextEra Energy, Inc. trades at $88 (market cap $183.53B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: NextEra Energy, Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| NEE | SNY | |
|---|---|---|
Market Cap | $183.53B | $104.83B |
Sector | Utilities | Health |
52-Week High | $97.88 | $52.34 |
52-Week Low | $69.77 | $41.33 |
Enterprise Value | $285.94B | $121.32B |
Dividend Yield | 2.83% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $87.93, down 0.98% with a bearish technical signal. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though Q4 2025 earnings missed expectations. Recent news highlights the proposed Dominion Energy combination and $59 billion capital expenditure plan through 2032. Analyst consensus remains strongly bullish with 66.7% buy ratings and $101.88 price target, representing 16% upside potential.
NEE offers solid long-term growth prospects from renewable energy expansion and regulatory advantages, but faces execution risks from massive capital spending and integration challenges from the Dominion merger. Current valuation at 22.34 P/E appears reasonable given growth trajectory, though technical weakness suggests near-term consolidation may continue before potential breakout.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
